A Multi-Center, Single Arm, Phase II study of Pembrolizumab (MK-3475) in Combination with Chemotherapy for Patients with Advanced Colorectal Cancer: HCRN GI14-186

For full description, see www.clinicaltrials.gov.

Manuscripts/Articles:

• CJ Herting, MR Farren, Y Tong, Z Liu, B O’Neil, T Bekaii-Saab, A Noonan, C McQuinn, TA Mace, W Shaib, C Wu, BF El-Rayes, S Shahda, GB Lesinski. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunology, Immunotherapy (2021): https://doi.org/10.1007/s00262-021-02986-5. See abstract.

Abstracts/Posters/Presentations:

• S Shahda, AM Noonan, TS Bekaii-Saab, BH O’Neil, A Sehdev, WL Shaib, PR Helft, PJ Loehrer, Y Tong, Z Liu, BF El-Rayes. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer. Accepted to Poster Session at the 2017 ASCO Annual Meeting. See abstract.